Systemic Mastocytosis, Diagnosis & Subtyping

Diagnosis and risk-stratified subtyping of systemic mastocytosis (SM) by WHO/ICC criteria. Confirms SM (1 major + 1 minor, or ≥3 minor criteria), then separates indolent SM (symptom-directed care, avapritinib for symptomatic disease) from advanced SM (ASM, SM-AHN, mast cell leukemia, KIT inhibitors midostaurin/avapritinib and cytoreduction). KIT D816V (imatinib-resistant) drives >90% of cases; bone marrow biopsy is required.

Evidence tier: Expert consensus. Reflects expert-consensus criteria, not a prospectively validated instrument. Apply clinical judgment and local policy.

Decision points

  • Do WHO criteria confirm systemic mastocytosis?
  • Advanced SM (C-findings), or indolent disease?

Do-not-miss pitfalls

  • KIT D816V (>90% of adult SM) is RESISTANT to imatinib, do not treat SM with imatinib. Use D816V-active inhibitors (avapritinib, midostaurin). Imatinib is reserved for the rare D816V-negative, imatinib-sensitive KIT variants.
  • Bone marrow biopsy is required to diagnose and stage SM, skin findings and an elevated tryptase are not sufficient. Use a high-sensitivity (allele-specific) assay for KIT D816V, which can be detected in peripheral blood.
  • Elevated baseline tryptase has confounders, hereditary alpha-tryptasemia (extra TPSAB1 gene copies) raises tryptase without mastocytosis and co-occurs with SM. A tryptase >20 is only one minor criterion, not a diagnosis.
  • C-findings (organ damage) define ADVANCED disease and the need for cytoreduction; B-findings (high burden without dysfunction) indicate smoldering disease. Distinguishing them changes treatment entirely, do not conflate high mast-cell burden with organ damage.
  • Indolent SM carries a high anaphylaxis risk, especially to Hymenoptera stings, prescribe self-injectable epinephrine and refer for venom immunotherapy, which is indicated and generally lifelong in this group.
  • Osteoporosis is common and underdiagnosed in SM, screen with DXA at diagnosis; vertebral fractures can be the presenting feature.
  • Avapritinib should be used cautiously at very high platelet-lowering doses and is associated with intracranial bleeding at higher doses, follow approved dosing (25 mg/day for ISM) and monitor platelets.
  • SM-AHN requires treating BOTH components, the mastocytosis and the associated hematologic neoplasm are managed on their own merits; controlling one does not control the other.

Evidence & citations

  1. Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98(7):1097-1116. PMID 37309222
  2. Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5(11):e646. PMID 34901755
  3. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530-2541. PMID 27355533
  4. Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27(12):2192-2199. PMID 34873345

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.